A novel nucleolin-binding peptide for Cancer Theranostics.

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Cancer-specific ligands offer targeted drug delivery, overcoming limitations of nanoparticles and antibodies.
• Peptides exhibit superior biocompatibility, low immunogenicity, and form non-toxic metabolites.
• Development of novel, site-specific cancer-targeting ligands is crucial for effective cancer therapy.

Purpose of the Study:

• To develop a novel cancer-specific peptide ligand for targeted drug delivery.
• To evaluate the efficacy of a paclitaxel-conjugated peptide in inhibiting cancer growth.
• To identify the specific cancer cell target of the novel peptide ligand.

Main Methods:

• Employed one-bead-one-compound (OBOC) combinatorial chemistry and multiple-antigen-peptide (MAP) synthesis for peptide screening.
• Utilized in vitro assays (whole-cell binding, flow cytometry, confocal microscopy) to assess peptide specificity.
• Evaluated in vivo efficacy and tissue distribution in xenograft mouse models using paclitaxel-conjugated peptide.

Main Results:

• Identified AGM-330 as a peptide ligand that specifically binds to cancer cells both in vitro and in vivo.
• Paclitaxel-conjugated AGM-330 demonstrated significantly enhanced inhibition of cancer cell growth compared to paclitaxel alone.
• Confirmed membrane nucleolin (NCL) as the target of AGM-330, noting its overexpression on cancer cell membranes and its role in cancer cell growth.

Conclusions:

• NCL-targeting peptide AGM-330 shows significant potential for targeted cancer drug delivery.
• The study highlights the therapeutic potential of targeting membrane NCL in cancer treatment.
• AGM-330 holds promise for both cancer diagnosis and targeted therapeutic applications.